Worth reading
61In focus
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Deterioration
Direction inferred from the company’s description.Scale
70522
¥ million (impairment loss)Wording
Avoiding a definitive answer
How definitive the wording is.Results for this period
Interim period (second quarter)1 April 2026 to 30 September 2026ConsolidatedIFRSNet Sales624,501¥ millionYear on year +16.7%Progress 51.2%
Operating profit70,802¥ millionYear on year -29.9%Progress 59.5%
Ordinary income69,523¥ millionYear on year -31.3%
Net income attributable to owners of the parent54,617¥ millionYear on year -29.0%Progress 62.4%
The width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
Net income per share¥37.02
Financial position at period-end
Total assets2,238,896¥ million
of which net assets 1,598,054 ¥ millionEquity ratio 71.4%vs. prior year-end +2.9pt
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Cash inflows and outflows
Operating+149,588
Investment-27,031
Financials-88,740
Net change+33,817
Stacked from zero: upward is an increase in cash, downward a decrease (in ¥ million).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
Cash and cash equivalents at end of period¥311,477 million
Segment revenueCardiovascular Company ¥372,286 million (YoY +15.6%), Medical Care Solutions Company ¥115,626 million (YoY +9.5%), Blood and Cell Technologies Company ¥124,794 million (YoY +16.5%), Organ Technologies Business ¥11,626 million
Segment profitSegment Cardiovascular Company / Current-period value ¥110,094 million / Year-ago period ¥87,016 million / yoy_pct Not disclosed, Segment Medical Care Solutions Company / Current-period value ¥12,410 million / Year-ago period ¥13,530 million / yoy_pct Not disclosed, Segment Blood and Cell Technologies Company / Current-period value ¥21,810 million / Year-ago period ¥15,623 million / yoy_pct Not disclosed, Segment Organ Technologies Business / Current-period value ¥1,675 million / Year-ago period ¥0 million / yoy_pct Not disclosed
Regional sales¥253,172 million (YoY +22.3%), ¥129,812 million (YoY +15.6%), ¥53,894 million (YoY +19.5%), ¥73,351 million (YoY +20.8%), ¥510,230 million (YoY +20.0%), ¥114,270 million (YoY +4.1%)
Outlook and shareholder returns
Full-year earnings forecast
Net Sales¥1,219,500 million (YoY +7.7%)
Adjusted operating profit¥271,500 million (YoY +23.8%)
Operating profit¥119,000 million (YoY -32.5%)
Ordinary incomeNot disclosed
Net income¥87,500 million (YoY -35.6%)
Revision to Earnings ForecastNot disclosed → Revenue ¥1,219,500 million (YoY +7.7%) / Adjusted operating profit ¥271,500 million (YoY +23.8%) / Operating profit ¥119,000 million (YoY -32.5%) / Profit for the year attributable to owners of the parent ¥87,500 million (YoY -35.6%)
Annual Dividend Forecast30 Yen → 36 Yen（+20.0%）
Factors Behind Changes in Business Performance
Revenue increased due to expanding medical demand and the contribution from foreign exchange, but operating profit and other profit measures declined due mainly to impairment losses related to the termination of a supply agreement with a major customer.
Disclosure regarding the going concern assumption
Not applicable.
Change in accounting policy
基準改正に伴う変更 Yesそれ以外の変更 No見積りの変更 No修正再表示 Not disclosed
Changes in the scope of consolidationAdded 0 companies; removed 0 companies.
Material subsequent eventsArsenal Medical, Inc. became a wholly owned subsidiary through a reverse triangular merger on 2 October 2026. The cash purchase consideration was approximately US$215 million, with contingent consideration payable upon the achievement of milestones.
Impairment loss¥70,522 million
Breakdown of extraordinary income (loss)Impairment loss ¥-70,121 million, Related expenses associated with impairment losses ¥-6,256 million, Expensing of the inventory step-up resulting from the fair value measurement of acquired assets ¥-5,120 million, Settlement proceeds received ¥20,100 million
Depreciation and amortization¥54,486 million
Availability of Supplementary Financial Results MaterialsYes
Availability of Financial Results BriefingYes (for securities analysts and institutional investors)
Issued Shares at Period-End1,480,559,680
Treasury Shares at Period-End5,326,447
| Item | Details |
|---|---|
| Fiscal Period Classification | Interim period (second quarter) |
| Accounting standards | IFRS |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 April 2026 to 30 September 2026 |
| Net Sales | ¥624,501 million (YoY +16.7%) |
| Operating profit | ¥70,802 million (YoY -29.9%) |
| Ordinary income | ¥69,523 million (YoY -31.3%) |
| Profit attributable to owners of the parent | ¥54,617 million (YoY -29.0%) |
| Net income per share | ¥37.02 |
| Equity ratio | End of the current fiscal period 71.4 / End of previous period 68.5 |
| Total assets | ¥2,238,896 million |
| Net assets | ¥1,598,054 million |
| Cash flows from operating activities | ¥149,588 million |
| Cash flows from investing activities | ¥-27,031 million |
| Cash flows from financing activities | ¥-88,740 million |
| Cash and cash equivalents at end of period | ¥311,477 million |
| Full-year earnings forecast | Net Sales ¥1,219,500 million (YoY +7.7%) / Adjusted operating profit ¥271,500 million (YoY +23.8%) / Operating profit ¥119,000 million (YoY -32.5%) / Ordinary income Not disclosed / Net income ¥87,500 million (YoY -35.6%) |
| Revision to Earnings Forecast | Not disclosed → Revenue ¥1,219,500 million (YoY +7.7%) / Adjusted operating profit ¥271,500 million (YoY +23.8%) / Operating profit ¥119,000 million (YoY -32.5%) / Profit for the year attributable to owners of the parent ¥87,500 million (YoY -35.6%) |
| Annual Dividend Forecast | 30 Yen → 36 Yen（+20.0%） |
| Segment revenue | Cardiovascular Company ¥372,286 million (YoY +15.6%), Medical Care Solutions Company ¥115,626 million (YoY +9.5%), Blood and Cell Technologies Company ¥124,794 million (YoY +16.5%), Organ Technologies Business ¥11,626 million |
| Segment profit | Segment Cardiovascular Company / Current-period value ¥110,094 million / Year-ago period ¥87,016 million / yoy_pct Not disclosed, Segment Medical Care Solutions Company / Current-period value ¥12,410 million / Year-ago period ¥13,530 million / yoy_pct Not disclosed, Segment Blood and Cell Technologies Company / Current-period value ¥21,810 million / Year-ago period ¥15,623 million / yoy_pct Not disclosed, Segment Organ Technologies Business / Current-period value ¥1,675 million / Year-ago period ¥0 million / yoy_pct Not disclosed |
| Regional sales | ¥253,172 million (YoY +22.3%), ¥129,812 million (YoY +15.6%), ¥53,894 million (YoY +19.5%), ¥73,351 million (YoY +20.8%), ¥510,230 million (YoY +20.0%), ¥114,270 million (YoY +4.1%) |
| Depreciation and amortization | ¥54,486 million |
| Impairment loss | ¥70,522 million |
| Breakdown of extraordinary income (loss) | Impairment loss ¥-70,121 million, Related expenses associated with impairment losses ¥-6,256 million, Expensing of the inventory step-up resulting from the fair value measurement of acquired assets ¥-5,120 million, Settlement proceeds received ¥20,100 million |
| Disclosure regarding the going concern assumption | Not applicable. |
| Change in accounting policy | Changes due to revisions to standards Yes / Other changes No / Change in accounting estimate No / Restatement Not disclosed |
| Changes in the scope of consolidation | Added 0 companies; removed 0 companies. |
| Material subsequent events | Arsenal Medical, Inc. became a wholly owned subsidiary through a reverse triangular merger on 2 October 2026. The cash purchase consideration was approximately US$215 million, with contingent consideration payable upon the achievement of milestones. |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | Yes (for securities analysts and institutional investors) |
| Issued Shares at Period-End | 1,480,559,680 |
| Treasury Shares at Period-End | 5,326,447 |
| Factors Behind Changes in Business Performance | Revenue increased due to expanding medical demand and the contribution from foreign exchange, but operating profit and other profit measures declined due mainly to impairment losses related to the termination of a supply agreement with a major customer. |
Items this document does not state (4)
Operating MarginPayout ratioShareholder Return PolicyOrders received and order backlog
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Although global medical demand expanded and foreign exchange movements were also positive, the earnings forecast reflected impairment losses on related assets following the termination of a supply agreement with a major customer, risks related to the voluntary recall of certain products and the value of related assets in the Aortic business, and temporary supply constraints in the Neuro business.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.